[Surgical treatment for 217 patients with bladder transitional carcinoma].
OBJECTIVE
Bladder transitional cell carcinoma (TCC) is the most common cancer among urogenital neoplasms. Surgical operation is the most effective therapy for TCC. This study was to explore surgical treatment for TCC and its clinical significance.


METHODS
Clinical data, including disease-free survival, recurrence and death, of 217 TCC patients who had received different surgical procedures were retrospectively analyzed.


RESULTS
After a median follow-up of 30 months, 195 patients were free of disease, recurrence was observed for 56 times. Fourteen patients died: 13 of them died of progressive disease, and 1 died of renal failure. None death occurred in patients with stage T1 or grade I tumor. The overall 2-year survival rate was 89.6%. The survival rate and disease-freely survival rate were negatively correlated to stage and grade of the tumors. The prognosis of stage T1 and T4 patients had no correlation to surgical procedures. For stage T2 and T3 tumors, the prognosis of the patients who received radical cystectomy was significantly better than that of the patients who received organ sparing procedure.


CONCLUSIONS
The organ sparing treatment is safe for patients with early stage and well differentiated TCC. Radical cystectomy should be done in time for patients with advanced and poorly differentiated TCC.
Yu
Shao-Long
SL
State Key Laboratory of Oncology in Southern China, Guangzhou, Guangdong 510060, P. R. China.
Zhou
Fang-Jian
FJ
Qin
Zi-Ke
ZK
Han
Hui
H
Liu
Zhuo-Wei
ZW
Wang
Bin
B
Wang
Huan
H
Li
Yong-Hong
YH
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002295:Carcinoma, Transitional Cell / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D015653:Cystectomy / Q000379:methods*; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*